< Back to news archive

CHEMCONNECTION AND CRISTAL THERAPEUTICS ANNOUNCE SUCCESSFUL GMP PRODUCTION OF CRIPEC® DOCETAXEL FOR PHASE 1/2A CLINICAL TRIALS

Oss and Maastricht, The Netherlands, June 1, 2016 – ChemConnection, a privately-held company manufacturing nanomedicines, bioconjugates, peptides, and small molecules, announces the successful GMP production of CriPec® docetaxel for its customer Cristal Therapeutics, a privately-held life sciences company developing nanomedicines against cancer and other diseases.

“ChemConnection has made a tremendous leap forward in becoming the global lead center for nanomedicines manufacturing” said Gerjan Kemperman, CEO of ChemConnection. “Recent investments in our manufacturing and analytical capabilities have boosted the advancement of nanomedicines. The successful completion of the process and analytical development, and GMP production of CriPec® docetaxel shows our expertise in sophisticated nanomedicine development and manufacturing. The continued partnership with Cristal Therapeutics will further strengthen our position in the nanomedicines manufacturing field.”

“We are very pleased with the partnership with ChemConnection on the scale up and GMP production of CriPec® docetaxel as being the lead product, based on our proprietary CriPec platform” said Joost Holthuis, CEO of Cristal Therapeutics. “The manufacturing of CriPec® docetaxel has resulted in a technical package that adds significant value to our portfolio and enabled the start of the clinical evaluation in patients with solid tumors.

Menu
class="last-menu-item menu-itemve-menu" class="">
  • Drug Substances
  • Nanomedicines
  • Analytical Sciences
  • News
  • About us
  • Contact